Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

https://www.globenewswire.com/news-release/2024/06/07/2895248/0/en/Zealand-Pharma-announces-that-Boehringer-Ingelheim-s-survodutide-demonstrates-breakthrough-improvement-in-liver-fibrosis-with-no-worsening-of-MASH-in-64-5-of-patients-with-F2-and-F.html

company announcement